Johnson & Johnson submits OTTAVA robotic surgical system to FDA
Johnson & Johnson submitted the OTTAVA robotic surgical system to FDA, supported by IDE study data.
Evidence notes
- Johnson & Johnson MedTech submitted the OTTAVA robotic surgical system to the U.S. FDA.
- The submission was supported by data from the system's investigational device exemption study.
- The event marks a regulatory milestone after first clinical cases were completed in 2025.
Company context
Johnson & Johnson is a global healthcare company with surgical robotics exposure through OTTAVA and Monarch within its medtech business.